Telix's TLX597-Tx Shows Promising Dosimetry Profile in Prostate Cancer Trial
Event summary
- Telix presented dosimetry results from the Phase 2 OPTIMAL-PSMA trial of TLX597-Tx at IPCS 2026, showing reduced radiation exposure to healthy organs.
- The trial evaluated an intensified dosing regimen in 120 men with advanced mCRPC, aiming to maximize tumor control while preserving quality-of-life.
- TLX597-Tx demonstrated significantly lower salivary gland and kidney uptake, supporting dose intensification.
- Telix is initiating the OPTIMAL-E Phase 2 study in androgen pathway-sensitive prostate cancer (mHSPC).
- TLX597-Tx is being developed alongside TLX591-Tx, Telix's lead antibody-based prostate cancer therapy candidate.
The big picture
Telix's TLX597-Tx represents a strategic push into earlier-stage prostate cancer treatment, complementing its existing pipeline. The favorable dosimetry profile positions TLX597-Tx as a potential differentiator in a competitive radiopharmaceutical landscape, where quality-of-life improvements are increasingly critical for patient adherence and clinical utility. The initiation of the OPTIMAL-E trial underscores Telix's commitment to expanding its portfolio in both mCRPC and mHSPC settings.
What we're watching
- Clinical Validation
- Whether TLX597-Tx can sustain its favorable dosimetry profile in larger, more diverse patient populations.
- Regulatory Pathway
- The pace at which Telix advances TLX597-Tx through Phase 2 and potential regulatory approvals.
- Competitive Positioning
- How TLX597-Tx differentiates itself from existing PSMA-targeting therapies in the prostate cancer treatment landscape.
Related topics